Literature DB >> 33410956

The Inflammatory and Fibrotic Patterns of Hepatic Stellate Cells Following Coagulation Factors (VII or X)-Shielded Adenovirus Infection.

Alireza Shiri1, Jamal Sarvari1,2, Saeed Firoozi Ghahestani1, Nasser Gholijani3, Ali Mohammad Tamaddon4,5, Mahroo Rastegari1, Afagh Moattari6, Seyed Younes Hosseini7.   

Abstract

The role of coagulation factors on the inflammatory effect of adenovirus (Ad) is an unresolved question that was considered herein. Adenovirus-36(Ad36) and adenovector-5-GFP(Ad5-GFP) were prepared; then, they were loaded with VII or FX factors. The size/charge parameters and transduction efficiency were evaluated using fluorescent microscopy and Zetasizer, respectively. The Ad36-coagulation factor complexes were added on the stellate cells, LX-2. Thereafter, the expression levels of inflammatory and fibrotic genes including PKR, IL-1β, TNF-α, TIMP-1, collagen, and TGF-β were measured by qPCR and ELISA assays. The loading of FVII or FX factors not only increased the size/charge of Ad5-GFP but also enhanced the transduction rate up to 60% and 75%, respectively, compared to the controls (45%). The PKR expression analysis showed an upregulation following treatment with all Ad36 forms (P = 0.0152). The IL-1β and TNF-α cytokines analyses demonstrated that the Ad36-FVII complex elicited the highest inflammatory response (P = 0.05). Similarly, the fibrosis-related expression analysis revealed a more inductive role of FVII when loaded on Ad36, compared to the FX factor. The findings suggested that adenovirus elicited the innate inflammatory and activation state in the hepatic stellate cell. In addition, adenovirus shielded by FVII exhibited more innate inflammation as well as activation of the stellate cells than the FX-loaded virus.

Entities:  

Keywords:  Adenovirus; Coagulation factor; Gene therapy; Hepatic stellate cell; Inflammation

Mesh:

Substances:

Year:  2021        PMID: 33410956     DOI: 10.1007/s00284-020-02297-5

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  34 in total

1.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Authors:  Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon N Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; Andre Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

Review 2.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

3.  Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.

Authors:  G Schiedner; N Morral; R J Parks; Y Wu; S C Koopmans; C Langston; F L Graham; A L Beaudet; S Kochanek
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

4.  Coagulation factor X activates innate immunity to human species C adenovirus.

Authors:  Konstantin Doronin; Justin W Flatt; Nelson C Di Paolo; Reeti Khare; Oleksandr Kalyuzhniy; Mauro Acchione; John P Sumida; Umeharu Ohto; Toshiyuki Shimizu; Sachiko Akashi-Takamura; Kensuke Miyake; James W MacDonald; Theo K Bammler; Richard P Beyer; Frederico M Farin; Phoebe L Stewart; Dmitry M Shayakhmetov
Journal:  Science       Date:  2012-09-27       Impact factor: 47.728

Review 5.  Clearance of activated stellate cells for hepatic fibrosis regression: molecular basis and translational potential.

Authors:  Desong Kong; Feng Zhang; Zili Zhang; Yin Lu; Shizhong Zheng
Journal:  Biomed Pharmacother       Date:  2012-11-15       Impact factor: 6.529

Review 6.  Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.

Authors:  William S M Wold; Karoly Toth
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391

7.  Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus).

Authors:  R Alba; A C Bradshaw; N Mestre-Francés; J-M Verdier; D Henaff; A H Baker
Journal:  Gene Ther       Date:  2011-06-16       Impact factor: 5.250

Review 8.  Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.

Authors:  Praveen K Bommareddy; Anand Patel; Saamia Hossain; Howard L Kaufman
Journal:  Am J Clin Dermatol       Date:  2017-02       Impact factor: 7.403

9.  The relevance of coagulation factor X protection of adenoviruses in human sera.

Authors:  M R Duffy; A Doszpoly; G Turner; S A Nicklin; A H Baker
Journal:  Gene Ther       Date:  2016-03-25       Impact factor: 5.250

10.  Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.

Authors:  Hasan Rehman; Ann W Silk; Michael P Kane; Howard L Kaufman
Journal:  J Immunother Cancer       Date:  2016-09-20       Impact factor: 13.751

View more
  1 in total

1.  To clot or not to clot? Ad is the question-Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia.

Authors:  Maha Othman; Alexander T Baker; Elena Gupalo; Abdelrahman Elsebaie; Carly M Bliss; Matthew T Rondina; David Lillicrap; Alan L Parker
Journal:  J Thromb Haemost       Date:  2021-08-23       Impact factor: 16.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.